Clearant's Initial Direct Sales Efforts Drive Sales of Sterile Implants.

LOS ANGELES -- Five Leading Medical Institutions Perform Surgeries throughout Country in First Month of Sales

Clearant, Inc. (OTCBB:CLRI) today announced that 17 Clearant Sterile Implant(R) cervical spinal and soft tissue allografts were distributed for upcoming surgeries in July, the first full month of the Company's new direct sales initiative. Cervical fusion and sports medicine surgeries using Clearant Sterile Implants were successfully performed at five leading medical institutions across the country in July.

Clearant recently launched its direct sales strategy by making Clearant Sterile Implants available directly to surgeons and clinics. The initiative has been met with enthusiasm in the surgeon community and generated substantial interest during the inaugural launch at the American Orthopedic Society for Sports Medicine (AOSSM) Annual meeting held in early July and throughout the month of July, including a total of 75 spinal and sports medicine surgeon interest requests.

"The responses that we have received from some of the top surgeons in the field to the Clearant Sterile Implant hard tissue have been overwhelmingly positive. The initial sales occurred in July, reflecting our ability to shorten the sales cycle," said Clearant Chief Executive Officer Alain Delongchamp. "We are now aggressively entering the next phase of our direct sales initiative and our sales team is working with surgeons to convert the many requests for information into additional sales."

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process, which substantially reduces all types of bacteria and viruses in biological products while maintaining the functionality of the underlying tissue implant or protein. The Company began to distribute directly to surgeons, hospitals and clinics Clearant Process sterile implants in June 2006; in addition, Clearant continues to license the Clearant Process and provides its patented sterilization services to tissue banks and other biological products manufacturers. As of the end of 1Q 2006, Clearant had 10 license and service agreements with tissue banks. To date more than 8,000 patients have been successfully implanted with Clearant Process sterile implants supplied by one of the Company's licensed partners. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the Clearant Process reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the Clearant Process can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, in particular statements regarding surgeons strongly recommending the use of implants with tissue treated by the CLEARANT PROCESS, and the conclusions from a study by surgeons to build demand for sterilized tissue. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, results of additional clinical studies, acceptance and success of our direct distribution of allografts, efficacy of the technology, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC, available on the SEC web site http://www.sec.gov.